Ionis Pharmaceuticals, Inc. (IONS)
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?
Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.
Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
Ionis Pharmaceuticals specializes in RNA-targeted therapies for neurological and cardiometabolic diseases using antisense DNA technology. The company has a robust pipeline with over 40 drug candidates, developed in partnership with major pharmaceutical companies and in-house. In 2024, Ionis launched Wainua for ATTRv-PN and Qalsody for SOD1-ALS, marking significant milestones in its product portfolio.
Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises
Ionis (IONS) reports better-than-expected top and bottom-line numbers for the second quarter of 2024.
Ionis Pharmaceuticals, Inc. (IONS) Q2 2024 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2024 Earnings Conference Call August 1, 2024 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Richard Geary - Executive Vice President and Chief Development Officer Kyle Jenne - Executive Vice President and Chief Global Product Strategy Officer Elizabeth Hougen - Executive Vice President and Chief Financial Officer Eric Swayze - Executive Vice President of Research Eugene Schneider - Executive Vice President, Chief Clinical Development and Operations Officer Jonathan Birchall - Chief Commercial Officer Conference Call Participants Amy Li - Jefferies Myles Minter - William Blair Yanan Zhu - Wells Fargo Securities Jessica Fye - JPMorgan Allison Bratzel - Piper Sandler Yaron Werber - TD Cowen Jason Gerberry - Bank of America Jay Olson - Oppenheimer Michael Ulz - Morgan Stanley Gary Nachman - Raymond James Salveen Richter - Goldman Sachs Kostas Biliouris - BMO Capital Markets Operator Good morning, and welcome to the Ionis Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.60 per share a year ago.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
Data from an early-stage study shows that treatment with Ionis' (IONS) ION582 helps improve communication, cognition and motor function in patients with Angelman syndrome, a rare nerve disorder.
Ionis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) HALOS Study of ION582 in Angelman Syndrome Conference Call July 22, 2024 8:00 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Holly Kordasiewicz - Senior Vice President, Neurology Elizabeth Jalazo - Assistant Professor of Pediatrics, Division of Genetics & Metabolism, University of North Carolina School of Medicine Becky Crean - Executive Director, Neurology Lynne Bird - Professor of Clinical Pediatrics, University of California, San Diego, Rady Children's Hospital San Diego Eugene Schneider - Executive Vice President, Chief Clinical Development and Operations Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities Denis Reznik - Raymond James David Lebowitz - Citi Amy Li - Jefferies Yanan Zhu - Wells Fargo Securities Jessica Fye - JPMorgan Jay Olson - Oppenheimer Gena Wang - Barclays Paul Matteis - Stifel Andy Chen - Wolfe Research Salveen Richter - Goldman Sachs Yale Jen - Laidlaw & Company Brendan Smith - Yaron Werber Kostas Biliouris - BMO Capital Markets Jason Gerberry - Bank of America Myles Minter - William Blair Operator Good morning and welcome to Ionis' Conference Call to discuss Ionis' HALOS Study Results. As a reminder, this call is being recorded.
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc IONS released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (AS).
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
